Cartesian's autoimmune CAR T looks durable, Arvinas’ LRRK2 data, and more: Clinical Report

A CAR T cell therapy designed for repeat dosing in autoimmune disease patients has shown durable efficacy after 12 months of follow up. Yet, its maker, Cartesian Therapeutics, like most other companies with positive data this week, got caught up in the market downturn. 

In a Phase IIb study, myasthenia gravis therapy Descartes-08 from Cartesian Therapeutics Inc. (NASDAQ:RNAC) led to an average reduction of 6.0 points on the Quantitative Myasthenia Gravis Score (QMG) at 12 months, after patients had received a course of six weekly doses. ...